FDAFDA recall D-0866-2026 · Sep 23, 2026
VITRUVIAS THERAPEUTICS INC: Thyroid Tablets recall
Recall found
Product
Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.
Reason for recall
Superpotent Drug
What to do
FDA enforcement reports don't include consumer instructions. Check the codes below against your packaging. If this is a medicine or device you use, talk to your pharmacist or doctor before you stop or change anything, and contact the company or FDA for what to do with the product.
Recall details
- FDA classification
- Class I: FDA's most serious class, where use of or exposure to the product may cause serious health problems or death.
- Status
- Ongoing
- Codes, lots and dates
- Lot # 504950, Exp Date: 09/30/2026.
- Quantity
- 1955 bottles
- Distribution
- US Nationwide.
- Recalling firm
- VITRUVIAS THERAPEUTICS INC, Auburn, AL
- Voluntary or mandated
- Voluntary: Firm initiated
- Recall started
- 2026-08-21
Source: openFDA enforcement record D-0866-2026 · search recall number D-0866-2026 in FDA's Enforcement Report.
Copied from the agency record without changes. Data as of Oct 22, 2026, 4:56 AM EDT. The agency notice is the final word.